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Pazienza V, Pomara C, Cappello F, Calogero R, Carrara M,
Mazzoccoli G, Vinciguerra M. The TRPA1 channel is a cardiac
target of mIGF-1/SIRT1 signaling. Am J Physiol Heart Circ
Physiol 307: H939 –H944, 2014. First published August 8, 2014;
doi:10.1152/ajpheart.00150.2014.—Cardiac overexpression of lo-
cally acting muscle-restricted (m)IGF-1 and the consequent down-
stream activation of NAD-dependent protein deacetylase sirtuin 1
(SIRT1) trigger potent cardiac antioxidative and antihypertrophic
effects. Transient receptor potential (TRP) cation channel A1
(TRPA1) belongs to the TRP ion channel family of molecular detec-
tors of thermal and chemical stimuli that activate sensory neurons to
produce pain. Recently, it has been shown that TRPA1 activity
influences blood pressure, but the significance of TRPA1 in the
cardiovascular system remains elusive. In the present work, using
genomic screening in mouse hearts, we found that TRPA1 is a target
of mIGF-1/SIRT1 signaling. TRPA1 expression is increased in the
heart of cardiac-restricted mIGF-1 transgenic (Tg) mice, both in
cardiomyocytes and noncardiomyocytes. In wild-type mice, SIRT1
occupied the TRPA1 promoter, inhibiting its expression, whereas in
the presence of the cardiac mIGF-1 transgene, SIRT1 was displaced
from the TRPA1 promoter, leading to an increase in its expression.
Cardiac-specific ablation of SIRT1 (cardiac-specific knockout) in
mIGF-1 Tg mice paradoxically did not increase TRPA1 expression.
We have recently reported a systemic “hormetic” effect in mIGF-1 Tg
mice, mild hypertension, which was depleted upon cardiac-specific
knockout of SIRT1. Administration of the selective TRPA1 antagonist
HC-030031 to mIGF-1 Tg mice restored blood pressure to basal
levels. We identified TRPA1 as a functional target of the cardiac
mIGF-1/SIRT1 signaling pathway, which may have pharmacological
implications for the management of cardiovascular stress.
transient receptor potential cation channel, subfamily A, member 1;
insulin-like growth factor-1; sirtuin 1; heart
CARDIOVASCULAR DISEASES are a leading cause of mortality,
representing one-third of all global deaths. IGF-1 and sirtuin-1
(SIRT1) are crucial mediators of cell homeostasis and cardio-
vascular stress (7). In mammals, a complex IGF-1 signaling
system with multiple alternative spliced isoforms displaying
distinct effects on cardiovascular function is in place (7). These
variants have a common core peptide, flanked by varying
termini (class 1 and 2 NH2-terminal peptides as well as E
peptides). IGF-1 is both a systemic growth factor produced by
the liver in response to growth hormone and a local growth
factor acting in an autocrine/paracrine manner in skeletal and
heart muscles. Muscle-restricted (m)IGF-1 is a locally acting
isoform that comprises class 1 NH2-terminal and Ea COOH-
terminal peptides (7). mIGF-1 boosts antioxidative cell defenses
by upregulating skeletal muscle or cardiac gene programs with
regenerative, antioxidant, and antiapoptotic properties (21, 27,
28). Moreover, mIGF-1 repairs the heart from injury through the
production of specific cytokines that recruit endothelium-primed
cells for de novo vascularization of myocardial tissue, indicating
that cardiomyocyte (CM)-specific overexpression of this trans-
gene might have profound systemic effects (20).
The SIRT family of NAD-dependent protein deacetylases
has been deeply implicated in the regulation of organism
healthspan (9). SIRT1 is the largest and best-characterized
member: its enzymatic activation triggers pleiotropic beneficial
effects (9). In fact, pharmacological or nutritional interventions
capable of activating SIRT1 have been shown to increase
lifespan in most model organisms (9). In contrast, SIRT1
knockout (KO) mice die at birth or soon after due to develop-
mental defects of the retina and heart (26). Moderate SIRT1
cardiac-specific overexpression has been shown to protect mice
from cardiac oxidative stress and postponed the onset of
age-dependent cardiac fibrosis and cell death, with increased
expression of antioxidants, such as catalase, through forkhead
box O-dependent mechanisms (1). In vitro and in vivo findings
have reinforced these cardioprotective effects of SIRT1, sug-
gesting that its activation might be of benefit for the treatment
of cardiac diseases (9). IGF-1 and SIRT1 actually can impinge
on the same signaling pathways (7, 25). In this respect, we
have shown that the liver-produced circulating IGF-1 isoform
and mIGF-1 display distinct effects in cardioprotection (29).
Using hypertrophic (ANG II)/oxidative (paraquat) stressors,
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we identified a signaling pathway that protects CMs and that
relies on mIGF-1-dependent SIRT1 activation (29, 30). For in
vivo studies in mice, we generated cardiac-specific mIGF-1
transgenic (Tg) mice in which SIRT1 was excised from adult
CMs in an inducible and conditional fashion [mIGF-1 Tg 
SIRT1 cardiac-specific KO (CKO)]. Functional and molecular
analyses of these animals confirmed that mIGF-1-induced
SIRT1 activity was required to protect the heart from oxidative
stress-induced cell damage and lethality (30). Moreover, we
uncovered unexpected systemic roles for the cardiac mIGF-1/
SIRT1 pathway in mice, among which mild hypertension (3).
The robust physiological responses obtained with mIGF-1-
induced SIRT1 activity suggested a potential mechanistic basis
for strategies to improve the outcome of heart disease. To
explore this more in depth at the molecular level, using a
high-throughput sequencing approach [chromatin immunopre-
cipitation (ChIP)-Seq], we identified new direct putative
genomic binding targets of nuclear SIRT1 in the heart (3):
among these, transient receptor potential (TRP) cation channel
A1 (TRPA1). This molecule belongs to the TRP ion channel
family of molecular detectors of thermal and chemical stimuli
that activate sensory neurons to produce pain (12). TRPA1 is
the smallest of the mammalian TRP superfamily of cation
channels, which comprises 28 members assigned to 6 subfam-
ilies based on sequence homology. These channels have been
strongly linked to the pathogenesis of clinical disorders, such
as cancer and inflammation (2, 13). TRPA1 activity might also
be implicated in the pathogenesis of cardiovascular disorders:
it is highly expressed in cerebral endothelial cells and smooth
muscle cells, and pharmacological or genetic modulation of its
activity influences blood pressure (BP) (6). However, the
significance of TRPA1 in the cardiovascular system is not
understood. For this reason, in this work, we explored the
relevance of TRPA1 as a target of cardioprotective mIGF-1/
SIRT1 signaling using mouse genetics as a tool and BP as a
functional readout. We found that cardiac TRPA1 expression is
modulated by mIGF-1 and can translate the effects of this
growth factor on BP levels in a SIRT1-dependent manner.
METHODS
Animal models. Transgenic FVB mice carrying rat mIGF-1 cDNA
driven by the mouse -myosin heavy chain (MyHC) promoter (-
MyHC/mIGF-1) were generated and maintained as previously de-
scribed (21). SIRT1 floxed (Fl/Fl) mice were as previously described
(4) and acquired from The Jackson Laboratory. Tamoxifen-inducible
-MyHC/mER-CRE-mER Tg mice were crossed to SIRT1 Fl/Fl mice
to deplete SIRT1 expression in adult CMs (22) upon tamoxifen
administration. Mice were placed on tamoxifen-containing chow
(Harlan Special Diet TD.55125) at 4 mo of age for 2 wk, leading to
efficient and reproducible gene recombination (14). The mIGF-1
transgene was introduced by three-way crosses to generate -MyHC/
mIGF-1 Tg  -MyHC/mER-CRE-mER; SIRT1Fl/Fl mice (referred
to as mIGF-1 Tg  SIRT1 CKO mice) (30). PCR genotyping was
performed using genomic DNA from tail biopsies. For in vivo
inhibition of TRPA1 activity, mice were injected with the TRPA1
antagonist HC-030031 (20, 50, and 100 mg/kg ip dissolved in 10%
DMSO, Sigma-Aldrich) for 30 min, an effective time for this drug
adopted from previous studies and upon our preliminary experiments.
All mouse procedures were approved by University College London
(London, UK) and the European Molecular Biology Laboratory
(Monterotondo, Italy) Ethical Committees and were in accordance
with national and European regulations.
ChIP. Protein-DNA complexes were captured by fixing heart
homogenates from adult wild-type (WT) or mIGF-1 TG mice at a
resting state in 1% (vol/vol) formaldehyde (Sigma) for 10 min at room
temperature with gentle shaking. The reaction was quenched by the
addition of 0.125 M glycine for 5 min at room temperature. Cells were
washed (3 times) with cold PBS and resuspended in cell lysis buffer
(50 mM HEPES, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5%
Nonidet P-40, and 1 proteinase inhibitor; 1  107 cells/ml) on ice
for 10 min to release nuclei. Nuclei were pelleted (4,000 rpm, 10 min,
4°C) and resuspended in nuclei lysis buffer [140 mM NaCl, 10 mM
Tris·Cl (pH 8), 1% Nonidet P-40, and 1 proteinase inhibitor] on ice
for 10 min. Cells were sonicated using a Bioruptor Sonicating Wa-
terbath (Diagenode). Lysate (300 ml) was sonicated for 40 pulses of
30-s “on” 30-s “off” in 1.5-ml TPX Eppendorf tubes, with ice
replaced regularly to minimize overheating of samples. Chromatin
was pooled and centrifuged for at 13,000 rpm for 10 min at 4°C to
remove debris, and single-use aliquots (300 l) were used for immu-
noprecipitation or stored at 80°C. Chromatin was immunoprecipi-
tated by bringing each aliquot of chromatin to 1 ml with nuclei lysis
buffer proteinase inhibitor. Chromatin was precleared with 80 l of
ChIP-grade protein agarose A beads (Upstate) for 4 h at 4°C with
rotation and incubated overnight with 4 g of SIRT1 monoclonal
antibody (10E04, Millipore) or unrelated rabbit IgG polyclonal anti-
body (Chemicon) at 4°C with rotation. Immunoprecipitated com-
plexes were collected by incubation with 100 l of ChIP-blocked
protein A agarose beads (Upstate) for 4 h at 4°C with rotation, and
nonspecific complexes were removed by washing beads twice with
high-salt buffer [0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris·Cl (pH 8.1), and 500 mM NaCl], low-salt buffer [0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris·Cl (pH 8.1), and 150 mM
NaCl], LiCl buffer [0.25 M LiCl, 1% Nonidet P-40, 1% deoxycholic
acid, 1 mM EDTA, and 10 mM Tris·Cl (pH 8.1)], and TE buffer,
consisting of 10 mM Tris (pH 8.0) and 1 mM EDTA.. Washes were
performed for 5 min at 4°C with rotation, and beads were collected by
centrifugation at 3,000 rpm at 4°C for 3 min. DNA was eluted with
100 l elution buffer (1% SDS and 100 mM NaHCO3). Beads were
vortexed for 30 s and incubated at room temperature with rotation for
15 min, the process was repeated, and eluates were combined (200
l). Cross-links were reversed with 0.3 M NaCl by incubating at 65°C
overnight in a hybridization oven, and RNA was removed with RNase
A (Upstate) at 37°C for 30 min. Protein was removed by incubating
samples with proteinase K (Upstate) for 1 h at 45°C. DNA was purified
using a Qiagen PCR Purification Kit (Qiagen) and eluted in 30 l
distilled H2O. For ChIP, individual SIRT1 ChIP samples were pooled
and concentrated using a SpeedVac. PCR against regions 19–118,
77–176, and 285–384 from the transcription start site (TSS) was
performed in SIRT1 pulled down samples and input and no template
controls using Taq DNA Polymerase (catalog no. MO273, New
England BioLabs) and processed for gel electrophoresis. Primer
sequences were designed to amplify a region of 100 bp and are
available upon request.
BP measurement. Noninvasive assessment of BP was performed by
tail-cuff measurements (Visitech Systems, Apex, NC) as previously
described (17).
Quantitative real-time PCR. Total RNA was isolated from hearts
using TRIzol (Invitrogen). After RNA quality verification, 1–2 mg
were used to prepare cDNA (Ready-To-Go, T-Primed First-Strand
Kit, Amersham Bioscience). Quantitative PCR for SIRT1 was per-
formed using SYBR green (Sigma) in a Light-Cycler (Roche) in a
25-l volume with the following amplification program: 1) 1 cycle for
50°C for 2 min; 2) 1 cycle for 95°C for 10 min; 3) 40 cycles at 95°C
for 15 s, 60°C for 30 s, and 72°C for 30 s; and 4) 1 cycle at 72°C for
10 min. Primer sequences for TRPA1 were as follows: forward
5=-AAGCGGAGACTTGGACATGA-3= and reverse 5=-TAACGAG-
GCTCTGTGAAGCA-3=. UbiC, 18S rRNA (Rn18S), and GAPDH
transcripts were used as internal controls, according to the GeNorm
method (29). Primer sequences were as follows: UbiC, forward
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5=-AGCCCAGTGTTACCACCAAG-3= and reverse 5=-GCAA-
GAACTTTATTCAAAGTGCAA-3=; Rn18S, forward 5=-CGCG-
GTTCTATTTTGTTGGT-3= and reverse 5=-AGTCGGCATCGTT-
TATGGTC-3=; and GAPDH, forward 5=-AACTTTGGCATTGTG-
GAAGG-3= and reverse 5=-ACACATTGGGGGTAGGAACA-3=.
Primary CM isolation procedures. Excised mouse hearts were
perfused using a Langendorff perfusion apparatus with Ca2-free
Krebs-Ringer bicarbonate (KRB) solution containing collagenase
(1 mg/ml) until they became flaccid. Hearts were then chopped finely,
and the mince was agitated gently in the same medium to dissociate
individual cells. The resulting cell suspension was filtered to remove
undigested material, and CMs were separated from non-CMs (NCMs)
by sedimentation of CMs at 500 g for 2 min. The supernatant
containing NCMs was separated and further centrifuged at 1,500 g for
5 min to pellet cells. The Ca2 tolerance of the sediment containing
CMs was restored gently by resuspending it in KRB containing a
progressively higher concentration of Ca2 to a final concentration of
1 mM. Both CM and NCM sediments were stored in TRIzol (Invit-
rogen) for RNA analyses.
RNA in situ hybridization. In situ hybridization was performed as
previously described using the coding region of TRPA1 to generate
the RNA probe (10).
Statistical analysis. Results are expressed as means  SE. Com-
parisons were made using Student’s t-test. P values of 0.05 were
considered as significant.
RESULTS
SIRT1 displacement from the TRPA1 promoter in the myo-
cardium of mIGF-1 mice is associated with increased TRPA1
expression levels. ChIP-Seq screening for differential SIRT1
genomic binding sites in whole hearts from WT versus cardiac-
restricted mIGF-1 Tg mice led to the identification of a few
dozens of differential SIRT1 genomic binding sites (33 sites
specific for WT mice and 32 sites specific for mIGF-1 Tg mice)
(3). In this ChIP-Seq data set, SIRT1 showed threefold enrich-
ment in the occupancy of the TRPA1 gene body in WT hearts
compared with mIGF-1 Tg hearts (3). In the present study, we
sought to validate these high-throughput sequencing data by
canonical ChIP using a specific ChIP-grade anti-SIRT1 anti-
body followed by quantitative PCR amplification of three
distinct selected promoter regions (19–118, 77–176, and 285–
384) from the TSS, respectively. As shown in Fig. 1, in the
presence of the mIGF-1 transgene, the binding of SIRT1 to
these promoter regions was almost undetectable, indicating
SIRT1 removal and suggesting that TRPA1 is a molecular
target of the mIGF-1/SIRT1 pathway. TRPA1 is a cation
channel involved in several clinical disorders; preliminary
evidence links TRPA1 activity to vasodilation and vasocon-
striction (18), although its cardiac expression levels and its role
in cardiovascular biology are not clear. Here, using RNA in
situ hybridization, we found that the TRPA1 transcript was
massively upregulated in the hearts of mIGF-1 Tg versus WT
mice (Fig. 2A). The TRPA1 signal localized to myocardial
fibers (Fig. 2A). To understand if TRPA1 was differently
ChIP: SirT1
PCR: TRPA1 promoter
Reg 2 (77-176)Reg 1 (19-118)
mIGF-1WT mIGF-1WT mIGF-1WT
Reg 3 (285-384)
Fig. 1. Sirtuin 1 (SIRT1) occupancy of the transient receptor potential cation
channel A1 (TRPA1) promoter in the myocardium of wild-type (WT) and
muscle-restricted (m)IGF-1 mice. Chromatin was isolated from whole hearts of
WT and mIGF-1 transgenic (TG) mice and processed for chromatin immuno-
precipitation (ChIP) using a SIRT1 antibody. PCR products of three distinct
regions of the TRPA1 gene promoter [19–118 (Reg 1), 77–176 (Reg 2), and
285–384 (Reg 3)], of 100 bp of length each, were separated by gel electro-
phoresis. Input was used as a control. Two representative WT and mIGF-1 TG









































Fig. 2. TRPA1 mRNA expression in cardiac muscle of WT and mIGF-1 Tg mice. A: mRNA hybridization in situ to detect TRPA1 mRNA expression. Hearts
from 4-mo-old adult animals were dissected, fixed overnight in 4% paraformaldehyde, and processed for whole mount in situ hybridization. Detection of
transcripts on paraffin sections was performed using digoxigenin-labeled hybridization probes against the TRPA1 coding region. Two serial sections of a
representative animal per group are shown. B: expression levels of TRPA1 mRNA were examined by quantitative RT-PCR in cardiomyocyte (CM) and non-CM
(NCM) fractions of WT and mIGF-1 Tg mouse hearts. UbiC, 18S rRNA (Rn18S), and GAPDH transcripts were used as internal controls, according to the
GeNorm method. Results are means  SE of 10 animals. ***P 	 0.001 vs. WT mice.
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expressed in CMs or NCMs (endothelial cells, fibroblasts,
macrophages, and smooth muscle cells, which comprises

50% of the total cardiac cell number), WT and mIGF-1 Tg
hearts were fractionated to separate CMs from NCMs (14, 30),
and TRPA1 mRNA levels were analyzed by quantitative PCR.
TRPA1 mRNA was found 5.5 times more expressed in the
CM fraction compared with the NCM fraction (Fig. 2B) in WT
hearts. A markedly higher expression in the CM fraction versus
the NCM fraction for TRPA1 was also found in the presence of
the cardiac mIGF-1 transgene (Fig. 2B). In mIGF-1 Tg hearts,
an 12.7-fold increase in TRPA1 mRNA expression in the
CM fraction was observed, without evident changes in the
NCM fraction, which comprised significantly higher expres-
sion values compared with WT hearts (Fig. 2B). These data are
consistent with the imaging in situ (Fig. 2A) and demonstrate that
1) TRPA1 is expressed more robustly in CMs compared with
NCMs and 2) TRPA1 is markedly upregulated by mIGF-1 in the
heart, specifically in CMs and not in NCMs (Fig. 2, A and B).
CM-specific inducible genetic ablation of SIRT1 in mIGF-1
mice lowers TRPA1 expression. Since SIRT1 is displaced
from the TRPA1 promoter in the myocardium in the pres-
ence of the mIGF-1 transgene, we investigated if genetic
ablation of SIRT1 could elicit the same effects. As previ-
ously reported (30), to ablate SIRT1 activity in the CM
compartment, we crossed CM-specific, tamoxifen-inducible
-MyHC/mER-CRE-mER Tg mice with conditional
SIRT1Fl/Fl KO mice to produce SIRT1 CKO mice. Cardiac
function and SIRT1 expression in these mice were unaltered
during growth and adulthood (30). After 2 wk on a tamoxifen-
enriched diet, 4-mo-old SIRT1 CKO mice displayed efficient
CM-specific SIRT1 inactivation (30). This did not occur in
tamoxifen-fed -MyHC/mER-CRE-mER WT mice or
SIRT1Fl/Fl mice and was cardiac specific. KO of cardiac SIRT1
in adult mice did not generate evident functional perturbations
(30). Using a three-way crossing of mIGF-1 Tg mice with
SIRT1 CKO mice, we next generated mIGF-1 Tg  SIRT1
CKO mice, which were born at the expected ratio and without
any abnormalities (30). Thus, we further sought to analyze four
groups of 4-mo-old mice for TRPA1 mRNA expression: WT,
mIGF-1 Tg  SIRT1Fl/Fl, SIRT1 CKO, and mIGF-1 Tg 
SIRT1 CKO mice. Upon feeding these four groups of mice a
tamoxifen-enriched diet for 2 wk, SIRT1 deletion occurred
specifically in the heart of SIRT1 CKO and mIGF-1 Tg 
SIRT1 CKO mice (30). Quantitative PCR analysis in CM and
NCM compartments revealed that ablation of SIRT1 alone in
CMs had no effects on TRPA1 expression in CMs and NCMs
compared with WT mice (SIRT1 CKO mice; Fig. 3). Moreover,
this gene expression analysis confirmed increased TRPA1 mRNA
levels in CMs of mIGF-1 Tg  SIRT1Fl/Fl mice (similar to
mIGF-1 Tg mice) compared with WT mice (Fig. 3); however,
TRPA1 mRNA expression returned to basal levels in the CM
compartment of mIGF-1 TG SIRT1 CKO mice (Fig. 3). These
data demonstrate that SIRT1 is required for the mIGF-1-
dependent upregulation in TRPA1 expression in CMs.
mIGF-1/SIRT1-dependent mild hypertension is prevented
by the systemic administration of the TRPA1 antagonist
HC-030031. Consistent with previous studies, noninvasive
measurements (17) of diastolic BP (DBP) and systolic BP
(SBP) in WT, mIGF-1 Tg, and mIGF-1 Tg  SIRT1 CKO
mice showed no differences between WT and mIGF-1 Tg 
SIRT1 CKO mice, whereas an 25% significant increase in
both DBP and SBP in mIGF-1 Tg mice compared with WT
littermates was observed in the basal state (Fig. 4) (3). In
mIGF-1 Tg  SIRT1 CKO mice, SBP, and to a lesser extent
DBP, was found restored to WT levels (Fig. 4). Given that
TRPA1 activity can modulate DBP and SBP in rodents (6), we
aimed to assess its potential impact on the mild hypertension
induced by cardiac overexpression of the mIGF-1 transgene in
a SIRT1-dependent fashion in mice. To this purpose, three
cohorts of mice (WT, mIGF-1 Tg, and mIGF-1 Tg  SIRT1
CKO mice) were intraperitoneally administered vehicle
(DMSO) or HC-030031, a selective TRPA1 channel blocker,
for 30 min at different doses (20, 50, and 100 mg/kg) before
DBP and SBP measurements. As shown in Fig. 4, administra-
tion of HC-030031 at 50 and 100 mg/kg blunted the high BPs,
both DBP and SBP, induced by the cardiac mIGF-1 transgene
in mice, whereas it had no significant inhibitory effects on the
other groups. These findings suggest that increased TRPA1
expression is instrumental for mIGF-1-induced mild hyperten-
sion in mice, since pharmacological inhibition of this channel

































Cardiomyocytes (CM) Non cardiomyocytes (NCM)
Fig. 3. Cardiomyocyte-specific inducible ge-
netic ablation of SIRT1 in mIGF-1 mice lowers
TRPA1 expression. All mice were 4 mo old and
placed for 2 wk under a tamoxifen diet. Upon
death, total RNA was extracted from CM and
NCM fractions of the hearts of WT, mIGF-1
Tg; SIRT1 floxed (SIRT1Fl/Fl), cardiac-specific
SIRT1 knockout (SIRT1 CKO), and mIGF
Tg  SIRT1 CKO mice. TRPA1 mRNA levels
were determined by quantitative PCR. UbiC,
Rn18S, and GAPDH transcripts were used as
internal controls, according to the GeNorm
method. Results are expressed as arbitrary units
and are means  SE of 8 animals. **P 	 0.01;
***P 	 0.001.
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DISCUSSION
In several experimental models, activation of mIGF-1 and
SIRT1 signaling pathways has proven effective in protecting
against cardiovascular stresses and ischemic insults (3, 7, 21,
29, 30). SIRT1 pharmacological activators have been devel-
oped and showed preclinical efficacy in cardioprotection
against infarct. We recently assessed that SIRT1 is located
within the nuclei of CMs (3), in contrast with other reports (23,
24), whereas it is located in the cytoplasm of NCM cell types.
ChIP-Seq offered us a powerful tool to determine how SIRT1
interacts with CM DNA (3), and we have provided the first
SIRT1 genome-wide DNA binding data set reported, after the
one obtained by Oberdoerferr et al. (16) in embryonic stem
cells with a ChIP-on-ChIP approach (16). This report (16)
described a few hundred genes bound by SIRT1 in the pro-
moter region in embryonic stem cells under basal conditions,
and under conditions of oxidative stress (H2O2 treatment), a
massive displacement of SIRT1, which goes to occupy other
promoters, was observed. In mouse hearts, we found that
SIRT1 similarly bound to 302 gene promoters, but there were
only a few dozen promoters exclusively bound by SIRT1 either
in the WT heart or in the mIGF-1 Tg heart (3). This distribution
indicates that the mIGF-1 transgene induces only subtle alter-
ations in SIRT1 DNA-binding patterns. Most interestingly,
these variations in mIGF-1/SIRT1 genomic (together with
transcriptomic) effects in unchallenged mouse hearts were
related to genes regulating functions beyond CM-specific ho-
meostatic mechanisms and relating to global body functions.
Interestingly, we found genes implicated in BP control (3).
Among these, we focused on TRPA1, since its gene body was
occupied abundantly by SIRT1 binding in WT hearts but not in
mIGF-1 Tg hearts. TRPA1 was first isolated in 1999 in a
screen for transformation-sensitive proteins in cultured fibro-
blasts (11), and it was subsequently shown to detect cold and
chemical stimuli that activate sensory neurons to produce pain
(12). More recent studies have extended our understanding of
TRPA1 functions, and it appears that its activity might also be
implicated in cardiovascular disorders and in modulating pres-
sure (6), making it a novel target in cardiovascular research.
TRPA1 is expressed in endothelial cells and smooth muscle
cells, and, in the present study, we report for the first time its
abundant expression at the level of mRNA in the CM cell fraction
versus the NCM fraction of the murine heart. We found that
TRPA1 mRNA is massively increased by the mIGF-1 cardiac
transgene in a SIRT1-dependent manner, since CM-specific in-
ducible genetic ablation of this deacetylase in the adult heart
restored TRPA1 to basal levels. An outstanding question opened
by our results is: “if displacement of SIRT1 from TRPA1 pro-
moter in mIGF-1 Tg mice increased cardiac expression of this
cation channel, why does genetic ablation of SIRT1 in the heart
paradoxically not have similar effects?” The cardiac epigenome
and transcriptome are intertwined in a very complex manner, and
the increase in SIRT1 activity/expression and global changes in
genome occupancy in the presence of mIGF-1 (3, 29, 30) might
affect a myriad of unidentified transcriptional cofactors (5) that
may contribute to activate TRPA1 transcription. Moreover,
mIGF-1 has multiple downstream effectors, such as serum/gluco-
corticoid-regulated kinase, pyruvate dehydrogenase kinase
isozyme 1, NF-B, and others (7, 21), that are able to cross-talk
with SIRT1: the disruption of this signaling interactome by ge-
netic depletion of SIRT1 might be involved in the absence of
TRPA1 upregulation in mIGF-1 Tg  SIRT1 CKO mice. The
regulation of TRPA1 gene transcription by growth factors and
stress-responsive signaling pathways is an untapped research
field. In addition, mIGF-1 activates an antioxidant gene program
in a SIRT1-dependent manner (1, 2). It has been demonstrated
that the transcription factor hypoxia-inducible factor (HIF)-1
protects the heart against oxidative and hypoxic stresses (3) and,
interestingly, activates TRPA1 gene transcription (4); HIF-1
activity is inhibited by SIRT1 through direct contact and deacety-
lation (5). Further studies should determine if in the absence of
SIRT1 occupancy on the TRPA1 promoter in the heart of mIGF-1
Tg mice, as we have shown, active HIF-1 could be crucial in
determining TRPA1 upregulation. It is surprising that mIGF-1 Tg
mice are mildly hypertensive and that inhibition of TRPA1 can
restore BP to basal levels, considering that BP is only partially
determined by the heart and mostly by peripheral vascular resis-
tance. The present study is limited by the lack of phenotyping the
level of BP by telemetry; further studies will be necessary to
assess the role of peripheral vascular resistance. The fact that the
mIGF-1 cardiac transgene can elicit other systemic effects, such
as an increase in the immune cell count and behavioral modifi-
cation (better performance in a fear conditioning test) (3), underlie
profound differences in the “circulome” of mIGF-1 Tg animals,
depending on molecules secreted by CMs in a autocrine and/or
paracrine fashion. In this respect, it has been shown that the
cardiac mIGF-1 transgene is proangiogenic: it can trigger the produc-
tion of cytokines that mobilize stem cells in the bone marrow to
form new blood vessels (20). In the present study, we found that
the effect of mIGF-1 on BP mediated by TRPA1 could be rescued
by CM-specific depletion of SIRT1, which, in turn, was not
associated with decreased cardiovascular performance (30). Of




















Fig. 4. mIGF-1/SIRT1-dependent mild hypertension is prevented by systemic
administration of the TRPA1 antagonist HC-030031. Noninvasive blood pres-
sure (BP) values in conscious mice were measured using the tail-cuff method
[diastolic BP (DBP) and systolic BP (SBP)] in a cohort of WT, mIGF-1 Tg,
and mIGF-1 Tg  SIRT1 CKO mice. Mice were intraperitoneally injected
with vehicle (DMSO) or, for blockage of TRPA1 activity, HC-030031 was
administered for 30 min at different doses (20, 50, and 100 mg/kg) before DBP
and SBP measurements. Results are means  SE of 8 animals for each
genotype. *P 	 0.01 vs. WT mice.
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ated with elevated BP, such as corticosterone and vasopressin, did
not show any change (data not shown), indicating a lack of overt
stress in the animal. This study does not rule out how the
BP-lowering effect of inhibition of the mIGF-1/SIRT1/TRPA1
pathway is related to the development of cardio-/cerebrovascular
diseases. However, although we lack an integrated physiological
understanding of cardiac mIGF-1 systemic function on multiple
distant target cell types, we propose that the moderate stress-
inducing properties of the cardioprotective mIGF-1 pathway are
coherent with the theory of hormesis, i.e., exposure to mild stress
should result in an adaptive response with various benefits (8, 19).
The role of TRPA1 in cardiovascular aging is unknown.
TRPA1 KO mice have been generated and characterized;
homozygous mice display behavioral deficits in response to
cold and mechanical stimuli (15). These animals have been
used mostly for pharmacological and neurological studies,
which showed that TRPA1 can also influence changes in BP in
connection to alterations in blood flow, vascular reactivity, and
autonomic system reflexes (18). This existing model could be
valuable to study TRPA1 activity regulation by growth hor-
mone-dependent signals and cardiac ischemic insults. Eluci-
dating in detail the systemic effects of TRPA1 and of other
targets of the mIGF-1/SIRT1 pathway may help to develop
new cardiac and antiaging strategies.
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